Faeth Therapeutics (FTH) Retained Earnings (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Retained Earnings came in at -$453.4 million in Q1 2026, down 7556566.67% YoY from N/an in Q1 2025, and down 45340100.0% on a QoQ basis from $1000.0 in Q4 2025.
Faeth Therapeutics (FTH) Retained Earnings (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Retained Earnings data on file, last reported at -$453.4 million in Q1 2026.
- Quarterly Retained Earnings fell 7556566.67% year-over-year to -$453.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$453.4 million (down 7556566.67% YoY) and the FY2025 annual result came in at $1000.0, up 107.69% from the prior year.
- Retained Earnings slipped to -$453.4 million in Q1 2026, from $1000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1000.0 in Q4 2025 to a low of -$453.4 million in Q1 2026.
- A 5-year average of -$120.2 million and a median of -$1.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings soared 107.69% — and 2026, when it tumbled 7556566.67%.
- Tracing FTH's Retained Earnings over 5 years: stood at -$1.0 million in 2022, then plunged by 22997.11% to -$231.9 million in 2023, then jumped by 99.99% to -$13000.0 in 2024, then jumped by 107.69% to $1000.0 in 2025, then tumbled by 45340100.0% to -$453.4 million in 2026.
- The last three Retained Earnings figures came in at -$453.4 million (Q1 2026), $1000.0 (Q4 2025), and -$278.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | -469.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -469.40 Mn |
| Mar 31, 2026 | -453.40 Mn |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -278.42 Mn |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -6,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | -254.30 Mn |
| Jun 30, 2024 | -93,000.00 |
| Mar 31, 2024 | -239.90 Mn |
| Dec 31, 2023 | -231.90 Mn |
| Sep 30, 2023 | -224.48 Mn |
| Jun 30, 2023 | -549,000.00 |
| Mar 31, 2023 | -823,000.00 |
| Dec 31, 2022 | -1.00 Mn |
| Sep 30, 2022 | -185.56 Mn |
| Jun 30, 2022 | -172.10 Mn |
| Mar 31, 2022 | -899,000.00 |
| Dec 31, 2021 | -149.21 Mn |
| Sep 30, 2021 | -139.80 Mn |